Aberrant overexpression of RRM2 is frequently observed in various aggressive malignancies, including prostate cancer, where it facilitates cellular proliferation, epithelial-mesenchymal transition (EMT), and is associated with poor clinical outcomes (45–47). Here, RRM2 is linked to prostate carcinoma.